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Among other diseases characterized by the onset of cachexia, congestive heart failure takes a place of relevance, considering the
high prevalence of this pathology in most European countries and in the United States, and is undergoing a rapid increase in
developing countries. Actually, only few models of cardiac cachexia exist. Difficulties in the recruitment and follow-up of clinical
trials implicate that new reproducible and well-characterized animal models are pivotal in developing therapeutic strategies for
cachexia. We generated a new model of cardiac cachexia: a transgenic mouse expressing Tpr-Met receptor, the activated form of c-
Met receptor of hepatocyte growth factor, specifically in the heart. We showed that the cardiac-specific induction of Tpr-Met raises
a cardiac hypertrophic remodelling, which progresses into concentric hypertrophy with concomitant increase in Gdf15 mRNA
levels. Hypertrophy progresses to congestive heart failure with preserved ejection fraction, characterized by reduced body weight
gain and food intake and skeletal muscle wasting. Prevention trial by suppressing Tpr-Met showed that loss of body weight could
be prevented. Skeletal muscle wasting was also associated with altered gene expression profiling. We propose transgenic Tpr-Met
mice as a newmodel of cardiac cachexia, which will constitute a powerful tool to understand such complex pathology and test new
drugs/approaches at the preclinical level.
1. Introduction
Cachexia has been defined as a “a complex metabolic syn-
drome associated with underlying illness and characterized
by loss of muscle” [1]. Cardiologists have a clear interest
in the matter, since 10–15% of chronic heart failure (CHF)
patients experience weight loss and wasting of muscle [2], a
phenomenon described as cardiac cachexia [3, 4]. The treat-
ment of CHF has made significant advances over the last two
decades. Despite this, the clinical perspective remains poor.
The situation worsens considerably once muscle wasting is
diagnosed [2, 5].The factors that trigger the progression from
clinically and body weight-stable CHF to cardiac cachexia,
however, remain poorly understood.
Cachectic patients have significantly reduced fat and
bone tissue [6]. However, the major site of protein loss in
cachexia is skeletalmuscle [7]: skeletalmuscle is an important
repository of muscle proteins which are mobilized to provide
energy substrates and to sustain protein synthesis in other
vital organs.
While cancer patients are known to be prone to develop
cachexia, cardiac cachexia due to chronic heart failure takes
the lead in terms of absolute patient numbers [8].Despite this,
although a large number of animal studies were performed
to investigate novel treatments for heart failure, few studies
concentrated on cardiac cachexia [3].
Animal models which replicate the clinical findings of
cardiac cachexiamainly rely on surgical techniques including
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myocardial infarction and aortic banding [9]. Two other
models of cardiac cachexia have been developed so far [10].
Li et al. demonstrated that cardiac-specific overexpression of
calsequestrin, a sarcoplasmic reticulum Ca2+ storage protein,
resulted in chronic heart failure as evidenced by decreased
fractional shortening and cachexia [11]. Kato et al. used the
Dahl salt-sensitive rat as a model of cardiac cachexia; these
rats showed impaired growth and reduced food intake in
comparison with controls [12].
c-Met tyrosine kinase has been identified as the receptor
of the hepatocyte growth factor (HGF) [13]. In our previous
studies, we aimed at investigating Met’s role in the heart, by
constitutively activating the HGF/Met system through the
expression of Tpr-Met [14]. In the Tpr-Met oncoprotein, the
N-terminal region of Tpr, which includes two dimerization
motifs, is fused to the tyrosine kinase of Met, which is, thus,
constitutively active in the absence of the ligand [15]. By post-
natal cardiac-specific expression of Tpr-Met, we generated a
model of congestive HF leading to cardiac cachexia.
2. Materials and Methods
2.1. Ethics Statement. The use of mice for this study and all
animal procedures were approved by the Ethical Commission
of the University of Turin and by the Italian Ministry of
Health.
2.2. Conditional Cardiac Tpr-Met Mice. The single transgen-
ics (𝛼-MHC-tTA mouse and Tpr-Met-TRE-GFP responder
mouse) and bitransgenics were described in [14, 16, 17]. All
animals were in FVB 100% background. For genotyping of
mouse tail DNA extract, tTa-𝛼-MHC and eGFP primers were
used. Bitransgenic and control mice were conceived and
delivered in the presence of 0.01% Doxycycline Hydrochlo-
ride (DOX, MP Biomedicals) in drinking water, in order to
maintain suppressing the transgene, during in utero devel-
opment. The day following birth, DOX was removed from
drinking water to allow Tpr-Met expression in the postnatal
age. All animals were fed standard diet and water ad libitum
and were maintained on a 12 h light-dark cycle at 23 ± 2∘C
room temperature. Environmental enrichment was provided.
2.3. Echocardiography. Size and function of the left ventricle
were evaluated by high-resolution transthoracicm-mode and
two-dimensional echocardiography with Vevo 2100 echocar-
diograph (Visualsonics), as previously described in detail
[14, 18]. Fractional shortening and h/r ratio were calculated
using standard formulas. Cardiac functionwas assessedwhen
the heart rate was 350 to 450 bpm.
2.4. Sample Collection. Animals were sacrificed by cervical
dislocation and organs were immediately rinsed in ice-cold
PBS, grossly dried,weighted and immersed inRNAlater (Qia-
gen) overnight at 4∘C, and then deposited at −80∘C for long-
term storage, to preserve total mRNA/proteins. Hindlimbs
were excised and digested overnight with Proteinase K
(Euroclone). Tibias were scanned and measured using Image
J.Themean of weights of left and rightmuscles was calculated
and used for subsequent statistics. After excision of muscles,
tibias were excised and digested with proteases. The mean
tibia length was used for normalization.
2.5. Western Blot and RT-PCR. Protein and total RNA
extracts were prepared and analysed as described [14, 16, 17].
Proteins were separated by 8–10% SDS-PAGE and transferred
to Hybond C-Extra membranes (Amersham). Equal protein
loadingwas verified by PonceauS (Euroclone) staining.Mem-
branes were blocked in 10% BSA (Sigma Aldrich), incubated
overnight at 4∘ with the primary antibody diluted in 5% BSA,
and probed with horseradish peroxidase- (HRP-) conjugated
IgGs. Bands were detected using Supersignal West Pico
(Thermo Scientific) by Chemidoc XRS (Biorad). Unsaturated
images were used for quantification with Imagelab (Biorad).
Gapdh was used for normalization of MF20 protein bands in
the same gel [16]; Spectra Multicolor Broad Range or Page
Ruler reference protein ladder (Thermo Scientific) was used.
All the protein samples compared were loaded on the same
gel. 𝑛 = 6 ctrls and 𝑛 = 5 TM for WB.
2.6. Histology: Cross-Sectional Area (CSA). PBS-rinsed mus-
cles were fixed in freshly made 4% paraformaldehyde (Sigma
Aldrich) 4–8 hours at room temperature or overnight at
4∘ and then embedded in paraffin. Transversal 10 𝜇m thick
sections of the middle were prepared and stained with
hematoxylin and eosin. Images were taken with Leica DMRE
microscope. ImageProPlus 5.1 software was used for acqui-
sition. Fiber CSA delimited was measured using Image J as
described [14]. At least 250 CSA from nonoverlapping fields
were measured. 𝑛 = 7 TM and 𝑛 = 9 ctrls.
2.7. Illumina Gene Expression Profiling and Bioinformati-
cal Analysis. Processing of tissue and RNA and Illumina
technology were described in [17]. Wild-type and single
transgenics were used as controls. Cubic spline-normalized
probe intensity data and detection 𝑝 values were obtained
using GenomeStudio (Illumina). Subsequent data processing
included Log
2
and Log
2
Ratio transformation. Expander [19]
was used tomerge redundant probes byGene ID and generate
the heat map from Log
2
Ratio values, after standardization
(mean 0 and std 1) and using complete linkage type and Pear-
son correlation similarity measurement. Only genes showing
a fold change of more than 1.7 and a 𝑝 value of less than
0.05 were included in the analysis. Expander unsupervised
hierarchical clusteringwas used to identify clusters of up- and
downregulated genes.
2.8. Statistics. Data are expressed as relative values (mean ±
SD). In relative measures, controls are set at 1. Differences
between groups were determined by independent two-tailed
Student’s 𝑡-test.
3. Results and Discussion
3.1. Cardiac Concentric Hypertrophy Progresses to Marked
Heart Failure with Preserved Ejection Function at P27. To
obtain transgenic mice in which expression of Tpr-Met can
be specifically induced in cardiac muscle in a regulated
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manner, we adopted the Tet-Off technology [20]. The Tpr-
Met-TRE-GFP responder (Tpr-Met responder) construct was
assembled by inserting the cDNAs of Tpr-Met and GFP
reporter into the bidirectional plasmid pBI. We thus gener-
ated a gain-of-function transgenic model with tetracycline-
suppressible expression of Tpr-Met under control of the 𝛼-
myosin heavy chain (𝛼-MHC) promoter, for specific expres-
sion of the transgene in the heart [14]. Tpr-Met mice were
conceived and delivered in the presence of DOX, in order
to suppress Tpr-Met expression during in utero development.
The day following birth, DOX was removed from drinking
water to allow permanent Met activation in postnatal car-
diomyocytes. We have previously shown that cardiac-specific
postnatal expression of Tpr-Met oncoprotein leads to cardiac
hypertrophy and Tpr-Met mice die at ∼4 weeks after birth
(between P25 and P27) with signs of congestive heart failure,
lung edema, alopecia, ascites, dyspnea, cyanosis, and lethargy
[14].
At P27, Tpr-Met hearts displayed marked features of
cardiac hypertrophy [14], which was also shown by echocar-
diographic analysis putting in evidence significantly reduced
LV Volumes, in both diastole and systole, compared to
controls (Figure 1(a)). A pattern fitting in the human classifi-
cation of concentric hypertrophy [21] was further underlined
by the concomitant significant increase in thickness/radius
ratio (h/r) (Figure 1(b)), LV mass (Figure 1(c)), and LV
mass normalized on body weight (LV mass/BW) in Tpr-
Met mice, compared to controls (Figure 1(d)). Plotting
relative wall thickness (RWT) and normalized LV mass
(Figure 1(e)) showed an important shift of Tpr-Met hearts
towards the upper-right corner of the plot, further confirming
the diagnosis of concentric hypertrophy. Notably, at the age
of P27, Tpr-Met mice did not show systolic dysfunction
as assessed by ejection fraction (EF) measurement, but
rather a phenotype resembling heart failure with preserved
ejection fraction (HFpEF, Figure 1(f)). Indeed, HFpEF is
more frequently associated with concentric remodelling and
concentric hypertrophy, compared to normal or eccentric
geometry [22].
3.2.The Progression of Cardiac Hypertrophy to Heart Failure Is
Associated with a Progressive Increase in Cardiac Gdf15 Levels.
With themassive progressive increase in cardiac hypertrophy
from P21 to P27 (Figure 1(g)), also a corresponding dramatic
increase in cardiac growth differentiation factor 15 (Gdf15)
mRNA levels was observed (Figures 1(h) and 1(i)). Gdf15,
also referred to as macrophage-inhibitory cytokine 1 (Mic1),
a member of the transforming growth factor-𝛽 (TGF-𝛽)
family (Bootcov PNAS 1997), is not expressed in the heart
under physiological conditions but increases in response to
cardiovascular injuries (i.e., pressure overload, heart failure,
and ischemia/reperfusion) and is associated with cardiac
remodelling [23]. Higher circulating levels of Gdf15 have
been reported in CVDs [24, 25], and such elevations were
correlated with disease progression [26]. Notably, Gdf15 has
been suggested as a promising diagnostic and prognostic tool
forHFpEF [25, 27]. Consistently, we report that, in ourmodel,
cardiac levels ofGdf15 increase progressivelywith the severity
of cardiac hypertrophy (Figures 1(g)–1(i)).
Elevated Gdf15 concentrations may be the result of com-
pensating protective mechanisms for tissue repair. Indeed,
Gdf15 has shown antihypertrophic and cardioprotective
functions [28, 29]. However, beneficial adaptative effects
may be detrimental in the long-term. This molecule is
overexpressed in cachexia-associated diseases and is capable
of modulating appetite [30]. Increased circulating levels of
Gdf15 have been reported in patients with several types of
cancer [31]. Mice xenografted with tumours overexpressing
Gdf15 showed a degree of weight loss proportional to the
elevation of serum Gdf15 levels [32]. A direct action of the
circulating cytokine on feeding centres in the brain has been
also reported [32].
Gdf15 emerges, therefore, as a potential new target for
anticachectic therapies. So far, however, no therapies have
been identified that decrease the circulating levels of Gdf15
in patients with cardiovascular disease.
3.3. Heart Failure Leads to Cardiac Cachexia Syndrome,
Characterized by Loss of Body Weight, Reduced Body Weight
Gain, and Skeletal Muscle Wasting. Increased heart-to-body
weight ratio (cardiac hypertrophy) and enhanced lung-to-
body weight ratio (pulmonary congestion) were the most
impressive signs of cardiac failure at P27, as we have previ-
ously described [14].
To investigate such progression from body-weight stable
to failing conditions, each animal was placed in a single
case starting from P21. Body weight gain and food intake of
Tpr-Met mice and control littermates were evaluated starting
from the age of P14 and P22, respectively. At P27, Tpr-
Met mice showed marked (>27%) decrease in body weight
(Figure 2(a); 𝑛 = 18 controls and 𝑛 = 9 Tpr-Met). According
to Anker and Coats, when weight loss higher than 7.5%
of the previous normal weight is observed in heart failure
patients (for at least six months and without signs of other
primary cachectic states), cachexia should be diagnosed [33].
Decreased body weight at P27 resulted from a reduction
in body weight gain, which started from postnatal day P20
(Figure 2(b); 𝑛 = 8 controls and 𝑛 = 5 Tpr-Met). Cardiac
cachexia involves similar features of other forms of cachexia,
including anorexia. Food intake of Tpr-Met mice was still
normal at P22 but diminished significantly starting from
postnatal day 23 (Figure 2(c); 𝑛 = 8 controls and 𝑛 = 5
Tpr-Met).
According to its definition, cachexia is characterized by
loss of muscle. Hence, when signs of congestive heart failure
were clear, Tpr-Met mice were sacrificed and tissues were
collected and weighed. Muscle weights were normalized to
the respective tibia lengths. Cachectic Tpr-Met mice showed
wasted hindlimb muscles (Figure 3(a)) and had significantly
reduced skeletal muscle weight with respect to controls (TA,
SOL, and GSN; 𝑛 = 10 Tpr-Met and 𝑛 = 26 controls;
Figure 3(b)). Accordingly, the mean Cross-Sectional Area
of TA, SOL, and GSN muscle fibers of Tpr-Met mice was
reduced, with respect to controls (𝑛 = 9 controls and 𝑛 = 7
Tpr-Met for CSA; Figures 3(c)–3(e), left and middle graph).
The maximum value of fiber CSA was also significantly
reduced in TA and GSN muscles (Figures 3(c)–3(e), right
graphs).
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Figure 1: Progressive concentric hypertrophy is accompanied by increased Gdf15 expression in Tpr-Met expressing hearts. (a) At P27, Tpr-
Met hearts displayed echocardiographic features of cardiac hypertrophy, including significantly reduced LV Volumes, in both diastole and
systole, compared to controls. Hypertrophy was further underlined by a significant increase in thickness/radius ratio (h/r) (b), LV mass (c)
and LVmass normalized on body weight (LVmass/BW) (d), and relative wall thickness (RWT) (e) in Tpr-Metmice, compared to controls. (f)
At the age of P27, Tpr-Met mice showed preserved ejection fraction (EF). With the increase in the extent of cardiac hypertrophy from P21 to
P27, as shown by stereomicroscopy (g), a progressive increase in cardiac Gdf15 mRNA levels was observed from P21 (h) to P27 (i). ∗𝑝 < 0.05;
∗∗
𝑝 < 0.01; ∗∗∗𝑝 < 0.005.
In the sum, Tpr-Met mice suffering from heart failure
showed a marked decrease in body weight, body weight gain,
and food intake and showed skeletal muscle loss due to
muscle fiber atrophy, hence recapitulating the phenotype of
cardiac cachexia syndrome.
3.4. Suppressing Tpr-Met Expression at P21 Rescues Car-
diac Hypertrophy and Loss of Muscular Weight. The extent
to which hypertrophic remodelling is reversible is poorly
known. To this aim, at birth, Doxycycline (DOX) was with-
drawn from a group of Tpr-Met mice for 21 days in order to
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Figure 2: In Tpr-Met mice, progressive concentric hypertrophy leads to reduced body weight and food intake. Tpr-Met mice showed a
significant decrease in body weight (BW) (a), body weight gain (b), and daily food intake (c). Tpr-Met mice showed marked decrease in body
weight starting from postnatal day 20 (P20) and food intake starting from postnatal day 22 (P22). ∗𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.005.
activate Tpr-Met signaling; DOX was subsequently restored
to stop Tpr-Met expression. At study completion (P27), a
complete rescue of heart hypertrophy and lung edema was
obtained when suppressing Tpr-Met expression at P21, since
Tpr-Met mice showed normal heart and lung weights [34].
It has been demonstrated that the use of ACE inhibitors
and 𝛽-blockers can potentially delay (and eventually prevent)
the onset of cardiac cachexia [3]. Notably, the reduction in
body weight gain was completely rescued when Tpr-Met
transgene expression was suppressed by DOX administration
from P21 (Tpr-Met + DOX P27; 𝑛 = 4), perfectly overlapping
with values from littermate controls (𝑛 = 6) (Figure 4(a)).
After such prevention trial, Tpr-Met mice showed normal
body weight at P27 (Figure 4(b)), and, consistently, the
weight of TA, SOL, and GSNmuscles was increased to values
comparable with those of controls (𝑛 = 10 Tpr-Met, 𝑛 = 6
Tpr-Met + DOX P27, and 𝑛 = 26 controls; Figure 4(c)).
These data put in evidence the fact that solving the
hypertrophic phenotype, before the appearance of skeletal
muscle wasting, can prevent the onset of cardiac cachexia
in an effective way, even if cardiac hypertrophy is already
manifest.
3.5. Gene Expression Profiling of Wasting Gastrocnemius Mus-
cle. For the molecular analysis of wasting skeletal muscle,
we concentrated on gastrocnemius (GSN) muscle. In GSN
muscle, a marked decrease of MF20 protein level normalized
on Gapdh was shown (Figure 5), in accordance with the
loss of muscle fiber detected in terms of weight and Cross-
Sectional Area.
Then, we performed gene expression profiling with
Illumina technology on GSN muscle samples. Total RNA
from three cachectic Tpr-Met mice was compared to three
littermate controls. Standardization was applied to Log
2
absolute intensities and all subsequent analysis was per-
formed using Expander software. A cut-off of 𝑝 < 0.05
and fold change >1.7 was used. Unsupervised hierarchical
clustering was performed and the corresponding heat map
6 BioMed Research International
Ctrl TM
(a)
TA
∗∗∗
Ctrl
TM
SOL
∗∗∗
Ctrl
TM
0
0.5
1
1.5
2
N
or
m
al
iz
ed
 m
us
cle
 w
ei
gh
t
0
0.25
0.5
N
or
m
al
iz
ed
 m
us
cle
 w
ei
gh
t
GSN
∗
Ctrl
TM
0
1
2
3
4
5
6
N
or
m
al
iz
ed
 m
us
cle
 w
ei
gh
t
(b)
Control
Tpr-Met
800400 1200 16000
TA CSA (𝜇m2)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
D
en
sit
y 
pr
ob
ab
ili
ty
TA
∗∗
Ctrl
TM
0
100
200
300
400
500
600
700
800
Fi
be
r C
SA
 (𝜇
m
2
)
∗∗∗
TA
Ctrl
TM
0
200
400
600
800
1000
1200
1400
1600
𝜇
m
2
)
Fi
be
r m
ax
 C
SA
 (
(c)
Control
Tpr-Met
400 800 1200 16000
SOL CSA (𝜇m2)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
D
en
sit
y 
pr
ob
ab
ili
ty
SOL
∗∗∗
Ctrl
TM
0
100
200
300
400
500
Fi
be
r C
SA
 (𝜇
m
2
)
SOL
Ctrl
TM
0
200
400
600
800
1000
1200
1400
1600
Fi
be
r m
ax
 C
SA
 (𝜇
m
2
)
(d)
Control
Tpr-Met
400 800 1200 16000
GSN CSA (𝜇m2)
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
D
en
sit
y 
pr
ob
ab
ili
ty
∗∗
GSN
Ctrl
TM
0
100
200
300
400
500
Fi
be
r C
SA
 (𝜇
m
2
)
∗
GSN
Ctrl
TM
0
200
400
600
800
1000
1200
1400
1600
𝜇
m
2
)
Fi
be
r m
ax
 C
SA
 (
(e)
Figure 3: At P27, heart failure in Tpr-Met mice is associated with skeletal muscle wasting. Cachectic Tpr-Met mice had significantly reduced
skeletal muscle (a) mass and (b) weight with respect to controls (tibialis anterior: TA, soleus: SOL, and gastrocnemius: GSN). A shift towards
smaller fibers was recognized in all three muscles ((c)–(e), left graphs). Accordingly, the mean Cross-Sectional Area (CSA) of TA (c), SOL
(d), and GSN (e) muscle fibers of Tpr-Met mice was reduced with respect to controls (middle graphs). The maximum value of CSA was also
significantly reduced in TA (c) andGSN (e)muscles (right graphs). Consistently, muscles fromTpr-Metmice showed reduced areas andmass.
∗
𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.005.
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Figure 4: Suppressing Tpr-Met expression at P21 prevents loss of muscular weight at P27. Doxycycline (DOX) was withdrawn from a group
of Tpr-Met mice for 21 days in order to activate Tpr-Met signaling; DOX was subsequently restored. The reduction in body weight gain (a)
and (b) body weight (BW) was completely rescued when Tpr-Met transgene expression was suppressed by DOX administration (Tpr-Met +
DOX) from P21, perfectly overlapping with values from controls for the whole follow-up. (c) When suppressing Tpr-Met expression at P21,
the weight of tibialis anterior (TA), soleus (SOL), and gastrocnemius (GSN) muscles was normalized to values overlapping those of controls.
∗
𝑝 < 0.05; ∗∗𝑝 < 0.01; ∗∗∗𝑝 < 0.005.
was generated (Figure 6). 120 differentially expressed probes
were identified and then reduced to 107 unique genes. Among
these, 63 were downregulated and 44 genes were upregulated
(Supplementary Tables 1 and 2 in Supplementary Material
available online at http://dx.doi.org/10.1155/2016/9549036).
A number of genes were downregulated (Supplementary
Table 1), including those controlling energy metabolism:
muscle glycogen phosphorylase (Pygm) and phosphofruc-
tokinase (Pfkm), pyruvate dehydrogenase kinase 2 (Pdk2),
NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10
(Ndufa10), aldo-keto reductase family 7a5 (Akr7a5), and
isocitrate dehydrogenase 3 (NAD+) alpha (Idh3a). Also genes
regulating protein synthesis were downregulated: eukaryotic
translation initiation factor 2, subunit 3 (Eif2s3y), eukaryotic
translation elongation factor 1a2 (Eef1a2), and E2F transcrip-
tion factor 2 (E2f2) as well as myosin XVIIIa (Myo18a) and
heat shock protein 90b1 (Hsp90ab1).
We then performed classification of downregulated genes
into functional GO categories (Table 1) and KEGG pathways
(Table 2). Among the downregulated GO categories, we
found translation factor activity, nucleic acid and nucleotide
binding, regulation of metabolic process and phosphate
metabolic process, muscle system process, generation of
precursor metabolites and energy, and cellular protein
metabolic and biosynthetic processes. Among the downreg-
ulated KEGG pathways, we found tight and gap junctions,
galactose metabolism, metabolic pathways, oxidative phos-
phorylation, and insulin signaling pathway. Altogether, these
8 BioMed Research International
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Figure 5: Reduced myosin heavy chain content in gastrocnemius
muscle from cachectic Tpr-Met mice. Myosin heavy chain content
was quantified in the gastrocnemius muscle (GSN) of cachectic Tpr-
Met mice and normalized on Gapdh levels. ∗∗∗𝑝 < 0.005.
data suggest an alteration in metabolic activities and growth
processes.
On the other hand, among the upregulated genes (Sup-
plementary Table 2), we found tumour necrosis factor recep-
tor superfamily 12a (Tnfrsf12a), also known as the Tweak-
receptor (TweakR), as well as a number of cytokines and
chemokines. Accordingly with data shown in [35], our work
suggests the presence of an inflammatory response in the
muscle milieu. Indeed, among the upregulated GO cate-
gories and KEGG pathways, there were immune and defense
response, chemokine activity, and chemokine signaling path-
way cytokine-cytokine receptor interaction.
Finally, several genes regulating ion trafficking, home-
ostasis, and signaling were either upregulated (S100 cal-
cium binding protein A10 (S100a10), gap junction mem-
brane channel protein alpha 1 (Gja1), cytochrome P450,
and family 2e1 (Cyp2e1)) or downregulated (ryanodine
receptor 1 (Ryr1), cAMP dependent protein kinase alpha
(Prkaca), potassium voltage gated channel, Shaw-related
subfamily 1 (Kcnc1), calmodulin binding transcription activa-
tor 2 (Camta2), and calcium/calmodulin-dependent protein
kinase 2b (Camk2b)). Cation transport GO category and
calcium signaling pathway, long-term depression, and long-
termpotentiationKEGGpathwayswere enriched in the list of
downregulated genes. Indeed, disruptions in calcium signal-
ing have been implicated in cytokine-mediated disruptions
in skeletal muscle and function, at least in cancer cachexia
[36, 37].
By gene expression profiling and bioinformatical anal-
ysis, we found that genes and TFs associated with muscle
metabolism, growth, and protein synthesis were negatively
modulated. Indeed, the overall net catabolic dominance in
heart failure provokes systemic tissue wasting [38], and such
downregulation may have contributed to the suppression of
growth in wasting muscle.
On the other hand, genes associated with inflammation
were increased. Indeed, cytokines may play a significant role
in the progression of cardiac cachexia since they may directly
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Figure 6: Heat map of the gene expression profiling of wasting
gastrocnemius muscle from cachectic Tpr-Met mice. Total RNA
from gastrocnemius muscle (GSN) of cachectic Tpr-Met mice was
compared to littermate controls. Standardization was applied to
Log
2
absolute intensities. A cut-off of 𝑝 < 0.05 and fold change
>1.7 was used. Unsupervised hierarchical clustering was performed
and the corresponding heat map was generated. 107 unique genes
differentially expressed were identified.
affect peripheral skeletal muscle metabolism. A possible
underlying pathogenic mechanism for such effect might be
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Table 2: Enriched KEGG pathways in down- and upregulated genes (fold change > 1.7; 𝑝 < 0.05).Only categories significantly associated (𝑝
value < 0.05) are considered. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, number of enriched genes, 𝑝 value, enrichment
factor, and list of the genes enriched in each pathway are reported.
KEGG pathway Number ofgenes 𝑝 value
Enrichment
factor Gene list
Gene set: downregulated genes
Tight junction 2 0.0261 8.0 Actn3, Csda
Melanogenesis 3 8.18𝐸 − 4 16.5 Camk2b, Gnas, and Prkaca
Long-term depression 2 0.00871 14.3 Ryr1, Gnas
Arrhythmogenic right ventricular cardiomyopathy
(ARVC) 2 0.00789 15.0 Cacnb1, Actn3
GnRH signaling pathway 3 7.52𝐸 − 4 17.0 Camk2b, Gnas, and Prkaca
Prostate cancer 2 0.0119 12.2 Hsp90ab1, E2f2
Gap junction 2 0.0119 12.2 Gnas, Prkaca
Galactose metabolism 2 0.00103 42.4 Gaa, Pfkm
Glioma 2 0.00692 16.1 E2f2, Camk2b
Dilated cardiomyopathy 3 5.91𝐸 − 4 18.4 Cacnb1, Gnas, and Prkaca
Metabolic pathways 9 2.11𝐸 − 4 4.34
Adssl1, St3gal3, Cox10, Gaa,
Atp6v0a1, Gamt, Pfkm, Ndufa10,
and Idh3a
Oxidative phosphorylation 3 0.00266 10.9 Cox10, Atp6v0a1, and Ndufa10
Calcium signaling pathway 4 3.64𝐸 − 4 11.9 Ryr1, Camk2b, Gnas, and Prkaca
Insulin signaling pathway 3 0.00196 12.2 Pygm, Tsc2, and Prkaca
Lysosome 2 0.0185 9.61 Gaa, Atp6v0a1
Taste transduction 2 0.00499 19.1 Gnas, Prkaca
Progesterone-mediated oocyte maturation 2 0.0157 10.5 Hsp90ab1, Prkaca
Parkinson’s disease 2 0.0343 6.89 Ube2l3, Ndufa10
Long-term potentiation 2 0.00809 14.9 Camk2b, Prkaca
Hedgehog signaling pathway 2 0.00421 20.8 Csnk1e, Prkaca
Wnt signaling pathway 3 0.00276 10.8 Csnk1e, Camk2b, and Prkaca
Vascular smooth muscle contraction 2 0.0212 8.94 Gnas, Prkaca
MAPK signaling pathway 3 0.0132 6.11 Mapt, Cacnb1, and Prkaca
Starch and sucrose metabolism 2 0.00284 25.4 Pygm, Gaa
Gene set: upregulated genes
Chemokine signaling pathway 4 1.09𝐸 − 4 16.2 Ccl21c, Ccl21a, Ccl9, and Ccl7
Cytokine-cytokine receptor interaction 5 1.43𝐸 − 5 16.2 Tnfrsf12a, Ccl21c, Ccl21a, Ccl9,and Ccl7
found in enhanced activation of the transcription factor NF-
𝜅B [39]. In fact, chronic activation of this TF results in
skeletal muscle wasting resembling clinical cachexia [40].
Increased expression of proinflammatory cytokines in the
skeletal muscle has been demonstrated in cancer [37] and
chronic heart failure [35, 41]. Notably, circulating cytokine
levels do not correctly reflect tissue levels [35].
4. Conclusions
Only a few animalmodelswhich replicate the clinical findings
of cardiac cachexia have been generated [10]. However, some
of these mainly rely on surgical techniques [9]; following
these procedures, an increase in resources is required, due to
delay in cachexia onset and to the costs due to surgery itself.
Moreover, technical issues are still important in limiting the
preciseness and reproducibility of heart failure models. This
criticism has been overcome by means of transgenic mice
and Dahl salt-sensitive rats models. In the present study, we
propose a new animalmodel for research on cardiac cachexia,
characterized by high reproducibility and very fast timing.
Some pharmacological treatments for cardiac cachexia
have been suggested [42]. Notably, using short-term models
of cardiac cachexia could be the best choice for testing
the efficacy of a wide range of compounds, from those
which have already passed early tests for the development of
tolerance to the treatment to new innovative drugs. Notably,
in experimental animals, weight loss has been reversed by
12 BioMed Research International
neutralisation of tumour-produced Gdf15 with a monoclonal
antibody [30], encouraging further research to provide a new
effective therapy to patients suffering from cardiac cachexia.
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